Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods

• US 7,521,557 B2
• Filed: 05/09/2006
• Issued: 04/21/2009
• Est. Priority Date: 05/20/2005
• Status: Active Grant

• Current Assignee: Bristol-Myers Squibb Company
• Original Assignee: Bristol-Myers Squibb Company
• Inventors: Wang, Wei, Hamann, Lawrence G., Fevig, John M., Devasthale, Pratik
• Primary Examiner(s): Desai; Rita J
• Assistant Examiner(s): Mabry; John
• Application Number:
  US11/430,657
• Publication Number:
  US 20060264457A1
• Time in Patent Office: 1,078 Days
• Field of Search: 546/113
• US Class Current: 546/113
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

Compounds are provided having the formula (I)

wherein R, X, Y, Z, A and n are as defined herein, which are inhibitors of dipeptidyl peptidase IV and thus are useful in treating diabetes and related diseases.

Claims

1. A compound of formula (I)

2. The compound as defined in claim 1 having the structure

4. The compound as defined in claim 1 having the structure

5. The compound as defined in claim 1 having the structure

6. The compound as defined in claim 1 selected from

7. A composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable carrier thereof.

8. A composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable salt thereof.

9. A composition comprising a compound as defined in claim 1 in racemic or homochiral form as a free base or a pharmaceutically acceptable salt thereof.

3. A compound having the structure

10. A compound having the structure

13. A composition comprising a compound as defined in claim 10 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.

16. The compound as defined in claim 10 in racemic or homochiral form as a free base or a pharmaceutically acceptable salt thereof.

11. A compound having the structure

14. A composition comprising a compound as defined in claim 11 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.

17. The compound as defined in claim 11 in homochiral form as a free base or a pharmaceutically acceptable salt thereof.

12. A compound having the structure

15. A composition comprising a compound as defined in claim 12 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.

18. The compound as defined in claim 12 in homochiral form as a free base or a pharmaceutically acceptable salt thereof.

19. A compound having the structure